Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Abiomed, Inc.
  6. News
  7. Summary
    ABMD   US0036541003

ABIOMED, INC.

(ABMD)
SummaryQuotesChartsNewsRatingsCalendarCompanyFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD

11/16/2022 | 12:25pm EST

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abiomed, Inc. (NasdaqGS: ABMD) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Abiomed will receive $380.00 in cash for each share of Abiomed that they own and a non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-abmd/ to learn more.

Please note that the merger is structured as a tender offer, such that time may be of the essence.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.


ę Business Wire 2022
All news about ABIOMED, INC.
2022Abiomed Inc : Completion of Acquisition or Disposition of Assets, Notice of Delisting or F..
AQ
2022ABIOMED, Inc. Announces Management Changes
CI
2022ABIOMED, Inc. Announces Termination of Michael R. Minogue as Chief Executive Officer
CI
2022ABIOMED, Inc. Announces Termination of Todd A. Trapp as Chief Financial Officer
CI
2022Johnson & Johnson Closes Acquisition of Abiomed
MT
2022Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Health Care Equ..
CI
2022Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P Global BMI Index
CI
2022Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P TMI Index
CI
2022Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Equal Weighted
CI
2022Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500
CI
More news
Analyst Recommendations on ABIOMED, INC.
More recommendations
Chart ABIOMED, INC.
Duration : Period :
Abiomed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Thorsten Sie▀ Chief Technology Officer & Executive VP
Charles A. Simonton Chief Medical Officer & Executive Vice President
Laxmi N. Peri Senior Vice President-Engineering
Matt Plano Executive Vice President-Global Operations
David Fortunati Director
Sector and Competitors